Objectives: The article aims to explore the studies performed on suicide because of coronavirus disease 19 through a bibliometric analysis. A quantitative analysis of the topic furnishes data on the publication pattern, influential research journals, highly cited articles, productive countries and organizations, the authorship pattern, and the collaborative pattern between authors. Methods: Data regarding the type of documents, most cited articles, influential research journals, contributions per country, and so on were extracted for the study from the Scopus database. Data analysis and visualization were performed through R-Studio and the VOSviewer application. Results: A bibliometric analysis encompassing scientific contributions based on suicide or suicide-related ideation because of the coronavirus pandemic showed a total of 494 documents published in 230 journals/books. The articles published by proficient authors in reputed journals highlighted the key areas of research in the field. USA dominated the list of scientific production of countries contributing to 340 documents. Conclusion: The results provided by this analysis could act as a steppingstone for experts to design a roadmap for mental health research during the pandemic. Studies can be designed to gather information on mental health conditions across specific age groups. Research collaborations that facilitate the publication of pooled protocols and data are encouraged.

Objectives This article aims to analyse the impact of the pharmaceutical policy on the availability, accessibility and affordability of medicines to the Indian populace. The article delves into the shortcomings of the Drug Price Control Order 2013 and highlights its real‐world implications. Methods Published literature in the form of scientific articles on the proposed reforms that took place in the pharmaceutical policy was reviewed. The study used the memorandums, laws and government decisions published by the Department of Pharmaceuticals, Ministry of Health and Family Welfare and National Pharmaceutical Pricing Authority|National Pharmaceutical Pricing Authorities. Results The pharmaceutical policy in India underwent several changes during 2013–2020 to enhance the affordability and accessibility of drugs. The stringent policy hampered innovation due to the lack of profitability to the Multinational Companies. Moreover, it was found that the impact of the price control order on the low‐cost local generic manufacturers affected much of the country's price‐sensitive population. Conclusion The pharmaceutical policy of India needs to be amended to extend its benefit to its stakeholders. The government should shift its attention to improving the quality of drugs, increasing competition amongst manufacturers and enhancing the accessibility of medicines through state/centre sponsored initiatives.